NPI 1366565004: Open Payments
NPI 1366565004. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,971 in 109 payments from 19 companies in 2025. Trend: 2023 $4,429 · 2024 $4,126 · 2025 $2,971
Food & beverage: $2,752Education: $219
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 21 | $477 |
| Vanda Pharmaceuticals Inc. | 10 | $421 |
| Teva Pharmaceuticals USA, Inc. | 6 | $294 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $286 |
| ABBVIE INC. | 19 | $282 |
| Otsuka America Pharmaceutical, Inc. | 9 | $273 |
| Neurocrine BioSciences, Inc. | 13 | $231 |
| Alkermes, Inc. | 11 | $183 |
| Tris Pharma Inc | 2 | $121 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $112 |
Products named: Auvelity, CAPLYTA, REXULTI, VRAYLAR, INGREZZA, FANAPT, HETLIOZ, ARISTADA.
